Coming back from the US in the mid-nineties, I have vivid memories of how complex and exotic it was to create a biotech startup in Switzerland.
Origins and evolution of Swiss biotech
In 1998 representatives from the Swiss biotech industry gave the young industry a voice with the formation of the Swiss Biotech Association (SBA). We look back at the challenges met on the industry’s path to maturity and look forward to the key trends in its further evolution.
65 Years of the Swiss National Science Foundation
Swiss National Science Foundation (SNSF) has increasingly encouraged researchers to transfer their knowledge and technologies into industry and government for the benefit of the whole society.
Moving forward with Innosuisse
Past, present and future: the change of focus is particularly relevant to Innosuisse. On 1 January 2018, the organisation previously known as the Commission for Technology and Innovation (CTI) was transformed into Innosuisse.
Swiss biotech patents: A history of quantitative and qualitative growth
Switzerland has always been an important player in biotechnology and maintains its position amongst the leaders in the face of dynamic global developments.
NTN Swiss Biotech: Matchmaker for academia and industry
Switzerland’s biotech community has established the critical mass to compete internationally and it delivers innovative products and technologies which contribute strongly to a prosperous economy.
Biotech growth drives investment in Swiss production sites
There has been strong expansion in the manufacturing capacities for recombinant proteins and biologics in Switzerland, helping to make the chemistry, pharma and biotech sector Switzerland’s largest export industry.
Biogen locates largest plant in Luterbach
One of the pioneers in biotechnology, Biogen, is building its next-generation biologic manufacturing facility in Luterbach, Switzerland. It will be the company’s largest production site.
Retrospective: Biotech listings on SIX Swiss Exchange
An IPO is a veritable option for funding biotech companies. This has been proven by the successful listing of a number of companies on SIX Swiss Exchange in the past two decades.
2017 – What a year for the Swiss biotech sector!
The year 2017 started with an earthquake for the Swiss biotech sector as the Board of Directors of Actelion recommended to its shareholders to accept the takeover offer from Johnson & Johnson. The price of USD 30 billion was globally the largest amount paid in 2017 for a transaction in the life sciences industry